Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
GPS
GRIm score
LDH
Prognostik biomarker
immune checkpointinhibitor therapy
real-world data
serum parameters
solid malignancies
Journal
Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
10
5
2022
pubmed:
11
5
2022
medline:
12
5
2022
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) are regarded as a standard of care in multiple malignancies. We hypothesized that serum parameters are of prognostic value in ICI treated patients suffering from solid tumours. Data from 114 patients treated with ICIs for solid malignancies from 2015 to 2019 at the Medical University of Vienna were collected retrospectively. Data included baseline characteristics, cancer type, serum parameters such as lactate dehydrogenase (LDH), C-reactive protein (CRP), albumin (Alb) and lymphocyte counts as well as overall survival (OS) and progression free survival. Additionally, the Gustave Roussy Immune Score (GRIm score) and the Glasgow prognostic score (GPS) were calculated. Cox regression models including time-dependent effects and strata for tumour type were used. Prognostic factors were pre-selected using a relaxed LASSO approach. The majority of patients were male (64.9%). The most common cancer types were non-small cell lung cancer (30.7%) and renal cell carcinoma (21.9%). Increased LDH and CRP were associated with poor 6-month OS (Hazard ratios (HR)=1.16 and 1.06 per 20% LDH/CRP increase; 95% CI 1.07-1.26 and 95% CI 1.03-1.09, respectively; The results of this analysis suggest that serum parameters might have prognostic value for the outcome of cancer patients treated with ICI, regardless of the tumour type.Key messagesIn this retrospective analysis, 114 patients with solid tumours were included. The results of this analysis point out that pre-treatment LDH, CRP and albumin levels are strongly prognostic for a poor 6-month OS.In addition to that, a high GRIm-score and poor GPS were associated with a worse OS (GRIm: HR = 2.84, 95% CI 1.72-4.69;
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors (ICI) are regarded as a standard of care in multiple malignancies. We hypothesized that serum parameters are of prognostic value in ICI treated patients suffering from solid tumours.
METHODS
Data from 114 patients treated with ICIs for solid malignancies from 2015 to 2019 at the Medical University of Vienna were collected retrospectively. Data included baseline characteristics, cancer type, serum parameters such as lactate dehydrogenase (LDH), C-reactive protein (CRP), albumin (Alb) and lymphocyte counts as well as overall survival (OS) and progression free survival. Additionally, the Gustave Roussy Immune Score (GRIm score) and the Glasgow prognostic score (GPS) were calculated. Cox regression models including time-dependent effects and strata for tumour type were used. Prognostic factors were pre-selected using a relaxed LASSO approach.
RESULTS
The majority of patients were male (64.9%). The most common cancer types were non-small cell lung cancer (30.7%) and renal cell carcinoma (21.9%). Increased LDH and CRP were associated with poor 6-month OS (Hazard ratios (HR)=1.16 and 1.06 per 20% LDH/CRP increase; 95% CI 1.07-1.26 and 95% CI 1.03-1.09, respectively;
CONCLUSION
The results of this analysis suggest that serum parameters might have prognostic value for the outcome of cancer patients treated with ICI, regardless of the tumour type.Key messagesIn this retrospective analysis, 114 patients with solid tumours were included. The results of this analysis point out that pre-treatment LDH, CRP and albumin levels are strongly prognostic for a poor 6-month OS.In addition to that, a high GRIm-score and poor GPS were associated with a worse OS (GRIm: HR = 2.84, 95% CI 1.72-4.69;
Identifiants
pubmed: 35535695
doi: 10.1080/07853890.2022.2070660
pmc: PMC9103267
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers
0
C-Reactive Protein
9007-41-4
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1339-1349Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Anticancer Res. 2019 Mar;39(3):1455-1461
pubmed: 30842182
Clin Ther. 2020 Sep;42(9):1682-1698.e7
pubmed: 32747004
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33077515
Clin Med Insights Oncol. 2021 Mar 31;15:11795549211004489
pubmed: 34248362
Oncotarget. 2017 Oct 07;8(61):103117-103128
pubmed: 29262550
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
Cancer Immunol Immunother. 2020 Oct;69(10):1947-1958
pubmed: 32676716
Front Oncol. 2020 Jun 23;10:654
pubmed: 32656072
J Natl Compr Canc Netw. 2020 Oct 01;18(10):1322-1326
pubmed: 33022640
Clin Cancer Res. 2019 Feb 1;25(3):946-956
pubmed: 30297458
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Panminerva Med. 2017 Dec;59(4):332-337
pubmed: 27309261
J Pain Symptom Manage. 2015 Jun;49(6):1050-1058.e2
pubmed: 25542550
Lung Cancer. 2021 Feb;152:27-33
pubmed: 33341085
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunother Cancer. 2018 Feb 20;6(1):15
pubmed: 29463302
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Eur J Haematol. 2016 Sep;97(3):219-27
pubmed: 27147112
Cancer. 2020 Mar 15;126(6):1208-1216
pubmed: 31829450
Eur J Clin Invest. 2010 Jan;40(1):35-53
pubmed: 20055895
J Clin Med. 2021 Mar 02;10(5):
pubmed: 33801320
Ann Oncol. 2016 Jul;27(7):1185-9
pubmed: 27052655
Anticancer Res. 2017 Oct;37(10):5857-5862
pubmed: 28982912
World J Oncol. 2019 Apr;10(2):90-100
pubmed: 31068989
World J Oncol. 2019 Feb;10(1):55-61
pubmed: 30834052
J Clin Oncol. 2015 Apr 20;33(12):1389-96
pubmed: 25779565
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Acta Oncol. 2015 Jul;54(7):961-70
pubmed: 25984930
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Br J Cancer. 2016 Feb 2;114(3):256-61
pubmed: 26794281
J Clin Oncol. 2016 May 20;34(15):1741-7
pubmed: 27001565
Support Care Cancer. 2020 May;28(5):2071-2078
pubmed: 31900613
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Br J Cancer. 2017 Apr 25;116(9):1141-1147
pubmed: 28324889
ESMO Open. 2019 Aug 16;4(4):e000531
pubmed: 31555483
Oncology. 2022;100(2):114-123
pubmed: 34999587
BMJ Support Palliat Care. 2020 Jun;10(2):129-135
pubmed: 31806655
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Lung Cancer. 2020 Jan;139:140-145
pubmed: 31786476
World J Oncol. 2020 Jun;11(3):98-105
pubmed: 32494316
Clin Oncol (R Coll Radiol). 2020 Sep;32(9):553-561
pubmed: 32684503